Clinical study on the utility of allergy tests to detect IgE-mediated anaphylaxis after diclofenac etalhyaluronate administration.

IF 1.8 4区医学 Q3 RHEUMATOLOGY

Modern Rheumatology Pub Date : 2024-10-17 DOI:10.1093/mr/roae091

Yoshimichi Okayama, Koremasa Hayama, Shuhei Takada, Dai Muramatsu, Yuji Nobuoka, Akiko Yagami

{"title":"Clinical study on the utility of allergy tests to detect IgE-mediated anaphylaxis after diclofenac etalhyaluronate administration.","authors":"Yoshimichi Okayama, Koremasa Hayama, Shuhei Takada, Dai Muramatsu, Yuji Nobuoka, Akiko Yagami","doi":"10.1093/mr/roae091","DOIUrl":null,"url":null,"abstract":"Objectives: This study was conducted to investigate factors involved in anaphylaxis related to diclofenac etalhyaluronate (DEH) [product name: Joyclu® (JCL)] (containing DEH and macrogol 400), which is used to treat patients with osteoarthritis.Methods: Patients with osteoarthritis were divided into two groups that had (experienced patients) or had not experienced anaphylactic symptoms after JCL administration (non-experienced patients). Five tests performed to assess factors related to anaphylaxis consisted of a skin prick test (SPT) as the primary endpoint and the other tests including basophil activation test, allergen-specific IgE (sIgE) tests using enzyme-linked immunosorbent assay or immunochromatographic kits, and genetic study were secondary endpoints.Results: The SPT showed 4 (wheal)/7 (erythema) of 15 experienced patients and 0/3 of 19 non-experienced patients were positive for any of the test reagents containing DEH. The basophil activation test showed two experienced patients were positive for test reagents containing DEH. DEH- and diclofenac-sIgE were detected in 3 and 1 of 12 experienced patients, respectively. No clear results were shown in the other tests.Conclusions: DEH may be the main factor involved in the development of anaphylaxis. The SPT was more sensitive than the basophil activation and allergen-sIgE tests for identifying factors associated with anaphylaxis.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roae091","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study was conducted to investigate factors involved in anaphylaxis related to diclofenac etalhyaluronate (DEH) [product name: Joyclu® (JCL)] (containing DEH and macrogol 400), which is used to treat patients with osteoarthritis.

Methods: Patients with osteoarthritis were divided into two groups that had (experienced patients) or had not experienced anaphylactic symptoms after JCL administration (non-experienced patients). Five tests performed to assess factors related to anaphylaxis consisted of a skin prick test (SPT) as the primary endpoint and the other tests including basophil activation test, allergen-specific IgE (sIgE) tests using enzyme-linked immunosorbent assay or immunochromatographic kits, and genetic study were secondary endpoints.

Results: The SPT showed 4 (wheal)/7 (erythema) of 15 experienced patients and 0/3 of 19 non-experienced patients were positive for any of the test reagents containing DEH. The basophil activation test showed two experienced patients were positive for test reagents containing DEH. DEH- and diclofenac-sIgE were detected in 3 and 1 of 12 experienced patients, respectively. No clear results were shown in the other tests.

Conclusions: DEH may be the main factor involved in the development of anaphylaxis. The SPT was more sensitive than the basophil activation and allergen-sIgE tests for identifying factors associated with anaphylaxis.

查看原文本刊更多论文

关于过敏试验在检测服用双氯芬酸乙醛脲酸酯后 IgE 介导的过敏性休克中的实用性的临床研究。

研究目的本研究旨在探讨用于治疗骨关节炎患者的双氯芬酸等透明质酸盐（DEH）[产品名称：Joyclu®（JCL）]（含DEH和macrogol 400）引起过敏性休克的相关因素：方法：将骨关节炎患者分为两组，一组在服用 JCL 后出现过敏症状（有经验患者），另一组在服用 JCL 后未出现过敏症状（无经验患者）。为评估与过敏性休克有关的因素而进行的五项测试包括：皮肤点刺试验（SPT）为主要终点，其他测试包括嗜碱性粒细胞活化测试、使用酶联免疫吸附试验或免疫层析试剂盒进行的过敏原特异性 IgE（sIgE）测试以及基因研究为次要终点：SPT 结果显示，15 名有经验的患者中有 4 人（乳头状）/7 人（红斑）对含有 DEH 的任何检测试剂呈阳性，19 名无经验的患者中有 0/3 对任何检测试剂呈阳性。嗜碱性粒细胞活化测试显示，2 名经验丰富的患者对含有 DEH 的测试试剂呈阳性反应。在 12 名有经验的患者中，分别有 3 人和 1 人检测到 DEH 和双氯芬酸-IgE。结论：结论：DEH可能是导致过敏性休克的主要因素。在识别与过敏性休克相关的因素方面，SPT 比嗜碱性粒细胞活化和过敏原-SIgE 检测更敏感。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Modern Rheumatology RHEUMATOLOGY-

CiteScore

4.90

自引率

9.10%

发文量

146

审稿时长

1.5 months

期刊介绍： Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions